GB201009091D0 - Compounds for the treatment of clostridium difficile-associated disease - Google Patents

Compounds for the treatment of clostridium difficile-associated disease

Info

Publication number
GB201009091D0
GB201009091D0 GBGB1009091.8A GB201009091A GB201009091D0 GB 201009091 D0 GB201009091 D0 GB 201009091D0 GB 201009091 A GB201009091 A GB 201009091A GB 201009091 D0 GB201009091 D0 GB 201009091D0
Authority
GB
United Kingdom
Prior art keywords
compounds
treatment
associated disease
clostridium difficile
difficile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1009091.8A
Other versions
GB2480815A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Summit Therapeutics Ltd
Original Assignee
Summit Corp PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Summit Corp PLC filed Critical Summit Corp PLC
Priority to GB1009091A priority Critical patent/GB2480815A/en
Publication of GB201009091D0 publication Critical patent/GB201009091D0/en
Publication of GB2480815A publication Critical patent/GB2480815A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB1009091A 2010-06-01 2010-06-01 Compounds for the treatment of clostridium difficile-associated disease Withdrawn GB2480815A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1009091A GB2480815A (en) 2010-06-01 2010-06-01 Compounds for the treatment of clostridium difficile-associated disease

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1009091A GB2480815A (en) 2010-06-01 2010-06-01 Compounds for the treatment of clostridium difficile-associated disease

Publications (2)

Publication Number Publication Date
GB201009091D0 true GB201009091D0 (en) 2010-07-14
GB2480815A GB2480815A (en) 2011-12-07

Family

ID=42371256

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1009091A Withdrawn GB2480815A (en) 2010-06-01 2010-06-01 Compounds for the treatment of clostridium difficile-associated disease

Country Status (1)

Country Link
GB (1) GB2480815A (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021008407A (en) * 2017-10-02 2021-01-28 武田薬品工業株式会社 Heterocyclic compound

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008527032A (en) * 2005-01-19 2008-07-24 バイオリポックス エービー Thienopyrrole useful for the treatment of inflammation
WO2008073451A2 (en) * 2006-12-11 2008-06-19 Sirtris Pharmaceuticals, Inc. Benzoimidazole derivatives as sirtuin (sir) modulating compounds
JP2010513263A (en) * 2006-12-15 2010-04-30 ファイザー・プロダクツ・インク Benzimidazole derivatives
HUE027964T2 (en) * 2009-04-02 2016-11-28 Fund Centro Nac De Investig Oncologicas Carlos Iii Imidazo[2,1-b][1,3,4]thiadiazole derivatives
US8536180B2 (en) * 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
CA2765534C (en) * 2009-06-15 2018-09-18 Rigel Pharmaceuticals, Inc. Small molecule inhibitors of spleen tyrosine kinase (syk)

Also Published As

Publication number Publication date
GB2480815A (en) 2011-12-07

Similar Documents

Publication Publication Date Title
ZA201403795B (en) Formulations for the treatment of diabetes
EP2558493A4 (en) Antibodies for the treatment of clostridium difficile-associated infection and disease
HRP20160397T1 (en) Compounds for the treatment of clostridium difficile associated disease
GB201021103D0 (en) New compounds for the treatment of neurodegenerative diseases
EP2654745A4 (en) Composition for the treatment of skin conditions
EP2621498A4 (en) Combination treatment for dermatological conditions
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
EP2521569A4 (en) Combined treatment utilizing vb-201
EP2548439A4 (en) Plant disease control agent
PL2605764T3 (en) Compositions for the treatment of cancer
IL222479A (en) Methods for tissue engineering
EP2544686A4 (en) Combination methods for treatment of disease
EP2536436A4 (en) Antimir-451 for the treatment of polycythemias
EP2582410A4 (en) Methods for complex tissue engineering
EP2556161A4 (en) Methods for the treatment of autoimmune diseases
EP2601954A4 (en) Therapeutic agent for disease
GB201013060D0 (en) Compounds for the treatment of clostridium difficile associated disease
GB201009091D0 (en) Compounds for the treatment of clostridium difficile-associated disease
GB201013058D0 (en) Compounds for the treatment of clostridium difficile associated disease
GB201009085D0 (en) Compounds for the treatment of clostridium difficile associated disease
GB201009108D0 (en) Compounds for the treatment of clostridium difficile associated disease
GB201009090D0 (en) Compounds for the treatment of clostridium difficile associated disease
GB201009097D0 (en) Compounds for the treatment of clostridium difficile-associated disease
GB201009095D0 (en) Compounds for the treatment of clostridium difficile-associated disease
GB201106972D0 (en) Compounds for the treatment of clostridium difficile-associated disease

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)